Physician profile
Bakul Patel
NPI 1295881894
$47,224.23
in general payments reported to CMS, 2019-2025
61 companies · $4,744 in 2025
The $4,744 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,245 · 2020: $22K · 2021: $4,206 · 2022: $2,255 · 2023: $3,812 · 2024: $5,071 · 2025: $4,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $374 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,226.71 |
| Education | $374.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23,646.78 | 2019-2021 | |
| Abbvie INC. | $2,287.04 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $2,093.38 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $1,494.78 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Livanova USA, INC. | $1,407.10 | 2019 | |
| Neurocrine Biosciences, INC. | $1,380.98 | 2019-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $1,155.27 | 2020-2025 | Gocovri, Gocovri, Apokyn |
| Lilly USA, LLC | $1,059.24 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Lundbeck LLC | $939.11 | 2019-2025 | Rexulti, Vyepti |
| Pfizer INC. | $876.59 | 2019-2025 | |
| Ucb, INC. | $875.92 | 2022-2025 | Rystiggo, Briviact, Zilbrysq |
| Amneal Pharmaceuticals LLC | $838.09 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Otsuka America Pharmaceutical, INC. | $820.02 | 2019-2025 | Nuedexta, Rexulti |
| Biogen, INC. | $746.33 | 2022-2025 | Vumerity, Tysabri, Leqembi |
| Jazz Pharmaceuticals INC. | $695.40 | 2019-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bakul Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.